Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEG35156 with Chemotherapy in Refractory/Relapsed AML
NCT00363974Phase 2Completed
- Sponsor
- Aegera Therapeutics
- Start
- Oct 2005
- Primary completion
- Mar 2009
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of AEG35156 in acute myeloid leukemia (AML), sponsored by Aegera Therapeutics. Primary endpoint: Dose at which AEG35156 produces acceptable CR and toxicity rates. Started Oct 2005; status: completed.
02
Drugs
AEG35156
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00363974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363974.